About IntelGenx

IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films.

IntelGenx’s superior film technologies, including VersaFilm®, VetaFilm™ and VevaDerm™, allow for next generation pharmaceutical products that address unmet medical needs. IntelGenx’s innovative product pipeline offers significant benefits to patients and physicians for many therapeutic conditions.

IntelGenx's highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx's state-of-the-art manufacturing facility offers full service by providing lab-scale to pilot- and commercial-scale production. For more information, visit www.intelgenx.com.



Facts and figures

  • Sponsored 38 clinical studies, 7 pivotal studies and one phase 2 clinical trial.
  • Our employees have nearly 90 years of combined formulation experience
  • Our employees have more than 50 years of combined analytical experience
  • We have screened more than 100 small molecules for film applicability


Dwight Gorham has been our Chief Executive Officer since April 2023. He has an accomplished history of senior leadership success in the life sciences industry. In an executive management career spanning more than three decades, he most recently served as President and CEO of Pillar 5 Pharma Inc. (“Pillar 5”), a pharmaceutical contract manufacturing organization (“CMO”) with a specialty in sterile ophthalmic products. Before joining Pillar 5 in 2015, he served as Senior Vice President and General Manager Global Operations of Pharmascience Inc., a leading Canadian generic drug company with an international presence in over 60 countries. Prior to that, he held a variety of senior roles, including: President and CEO at Accucaps Industries Ltd., a leading North American Supplier of soft gelatin capsules to pharmaceutical, OTC, Nutritional, Health & Beauty, and Recreational markets; a variety of management assignments at the Burroughs Wellcome & Co. facility in Montreal, Quebec; President (Founding) of Draxis Pharma Inc., a CMO supplier of small volume parenteral and lyophilization products to the pharmaceutical industry; General Manager of Baker Cummings Ltd.; and Director of Operations at the Canadian arm of Glaxo plc (now GSK plc).

Andre Godin, CPA, CA., Mr. Godin has been our President and Chief Financial Officer since May 2019. He has previously served as our Executive Vice President and Chief Financial Officer since August 2015. Mr. Godin has more than 25 years of experience in the Biotech/Pharma industry and has a strong background in Capital Markets, Finance and Operations. Most recently, from April 2014 to April 2015, he served as Interim CEO and CFO of Neptune Technologies and Bioresources Inc. and both of its subsidiaries Acasti and NeuroBioPharm. He started with Neptune in April of 2003 as Vice President, Administration and Finance and was named its CFO in 2008. Prior to joining Neptune, Mr. Godin was President of a dietary supplement corporation and a corporate controller for a pharmaceutical corporation in OTC products. Mr. Godin holds a Bachelor of Business Administration degree from the University of Quebec in Montreal. He is a member of the Canadian Chartered Professional Accountants and the Canadian Institute of Chartered Accountants.

Nadine Paiement, M.Sc.,Ms. Paiement has been Vice President, Research and Development at IntelGenx Corp. since January 2016. Nadine Paiement has over 15 years of experience in pharmaceutical research and development. She has been with IntelGenx since June of 2005, where she grew into different positions including her most recent position as Senior Director, Research and Development. Prior to joining IntelGenx, from 1999 to 2005 Ms. Paiement worked as Formulation Scientist for Smartrix Technologies.

Nadine Paiement holds a M.Sc. degree in Polymer Chemistry from Sherbrooke University, Montreal, Quebec. She is co-inventor of IntelGenx's platform technology and contributed to multiple patents and pending patent applications.

David Kideckel, Ph.D., M.B.A., has been our Senior Vice President, Head of Corporate Development & Strategic Alliances at IntelGenx Corp. since March 2023. Dr. Kideckel brings over 15 years of business development, advisory, and capital markets experience to IntelGenx. In 2021, he founded the Kideckel Advisory Group Inc., where he advised growth-oriented companies on business and corporate development, capital markets and overall strategic initiatives. Prior to that and in 2017, Dr. Kideckel was recruited from industry to capital markets to build healthcare and life sciences equity research franchises, most recently serving as Managing Director, Senior Institutional Equity Research Analyst at ATB Capital Markets Inc. His industry and business development experience spans several senior healthcare and biotechnology roles, including at Alexion Pharmaceuticals, Inc. (acquired by AstraZeneca plc), the world leader in rare diseases.

Dr. Kideckel holds a Ph.D. in Neuroscience & Statistics from the University of Toronto’s Institute of Medical Science and an M.B.A. from the University of Toronto’s Rotman School of Management, where he was a Canadian Institutes of Health Research Science to Business Award recipient.

Tommy Kenny, J.D. LL.B M.Sc, Mr. Kenny has been with IntelGenx since 2016 and has been Senior Vice President, General Counsel of IntelGenx Corp. since April 2023. He is an attorney specializing in intellectual property and commercial pharmaceutical law, who has developed strong technical expertise across a range of legal functions, managing litigation and advising on commercial partnerships, while also building a strong intellectual property portfolio for the Company’s oral film technologies. He has held a number of progressive management positions at IntelGenx, most recently as Vice President, Intellectual Property and Legal Affairs, General Counsel of IntelGenx Corp. Prior to joining IntelGenx, Mr. Kenny was an attorney in a Montreal Intellectual Property Boutique law firm, advising clients on various intellectual property and commercial matters. While in private practice, a large portion of Mr. Kenny’s work concerned patent prosecution and patent infringement analysis as well as advising client on a broader level regarding building and maintaining an intellectual property portfolio.

Mr. Kenny holds a Juris Doctor in North American Common Law from the University of Montreal, a Bachelor of Law as well as a Master of Chemistry from the University of Sherbrooke, and a Bachelor of Science with honors in Chemistry from Bishop’s University.

Karen Kalayajian, CPA, took on additional responsibilities as Vice President, Finance of IntelGenx Corp. in April 2023, after having served as Senior Director, Corporate Services and Corporate Controller, since 2016. She is responsible for financial reporting, planning, treasury and taxation. Prior to joining IntelGenx, Ms. Kalayajian was Director of Finance of Neptune Technologies & Bioresources Inc. Previously, she held a series of progressive audit manager positions at Raymond Chabot Grant Thornton and WSBG. Ms. Kalayajian holds a Bachelor of Commerce, Accountancy from Concordia University and a Graduate Diploma in Accountancy from the John Molson School of Business.